Ultragenyx Pharmaceutical Inc.
RARE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001515673
In the last 90 days, Ultragenyx Pharmaceutical Inc. insiders filed 0 open-market purchases and 5 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $3.55B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ultragenyx Pharmaceutical Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 3 insiders, $339.7K in total
- Insiders trading
- 3
- Net value
- −$339.7K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ultragenyx Pharmaceutical Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 67,863 | Sep 15, 2026 | 5 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 92,562 | Aug 4, 2026 | 5 |
| Horn Howard | Chief Financial Officer | 96,295 | Aug 4, 2026 | 11 |
| Sanders Corazon (Corsee) D. | Director | 21,095 | Jun 15, 2026 | 2 |
| Welch Daniel G | Director | 40,441 | May 18, 2026 | 1 |
| Dunsire Deborah | Director | 38,566 | May 18, 2026 | 1 |
| Narachi Michael | Director | 40,441 | May 18, 2026 | 1 |
| Fust Matthew K | Director | 33,696 | May 18, 2026 | 1 |
| Suliman Shehnaaz | Director | 27,951 | May 18, 2026 | 1 |
| Ray Amrit | Director | 31,116 | May 18, 2026 | 1 |
| Crombez Eric | EVP and Chief Medical Officer | 111,189 | May 6, 2026 | 3 |
| Kakkis Emil D | President & CEO | 735,739 | Apr 20, 2026 | 2 |
| Huang Dennis Karl | See Remarks | 147,845 | Apr 20, 2026 | 2 |
| Pinion John Richard | See Remarks | 133,142 | Apr 20, 2026 | 2 |
| Harris Erik | EVP & Chief Commercial Officer | 118,410 | Apr 20, 2026 | 2 |
| Kassberg Thomas Richard | CBO & EVP | 264,730 | Mar 4, 2025 | 0 |
| Bedrosian Camille L | EVP and Chief Medical Officer | 46,720 | Mar 3, 2023 | 0 |
| Dier Mardi | CFO & Executive Vice President | 66,695 | Oct 17, 2022 | 0 |
| Ekman Lars | Director | 17,745 | Jun 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Kassberg Thomas RichardCBO & EVP | SSale | −286 | $81.14 | −$23.2K | −0.1%216.3K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Parschauer Karah HerdmanEVP and General Counsel | SSale | −310 | $81.14 | −$25.2K | −1.1%28.4K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Pinion John RichardSee Remarks | SSale | −358 | $81.14 | −$29.0K | −0.7%49.8K after | |
| Oct 14, 2021 (view filing) | Oct 12-14 | 2 days | Dier MardiCFO & Executive Vice President | SSale | −6.74K | $82.00 | −$552.5K | −14.8%38.8K after | 2 lots |
| Sep 9, 2021 (view filing) | Sep 8 | 1 day | Parschauer Karah HerdmanEVP and General Counsel | SSale | −7.34K | $100.65 | −$738.4K | −20.4%28.7K after | |
| Sep 2, 2021 (view filing) | Sep 1-2 | 1 day | Bedrosian Camille LEVP and Chief Medical Officer | SSale | −5.00K | $100.11 | −$500.5K | −11.4%38.8K after | 2 lots |
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Harris ErikEVP & Chief Commercial Officer | SSale | −375 | $91.53 | −$34.3K | −1.5%25.3K after |